News for Ligand Pharmaceuticals Incorporated (LGND)

U.S. stocks traded mostly lower midway through trading, with the Dow Jones index falling more than 450 points on Thursday. The Dow traded down 1.20% to 39,191....

U.S. stocks traded mixed this morning, with the Dow Jones index falling more than 1% on Thursday. Following the market opening Thursday, the Dow traded down 1....

Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos' ZELSUVMIâ„¢

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and Channel Therapeutics Corporation (NYSE:CHRO) on Thursday signed a definitive merger agreement to combine Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc. (collectively Pelthos) with CHRO Merger Sub Inc., a wholly owned subsidiary of Channel. The merger will be supported by $50 million in capital raised from a group of strategic investors led by Murchinson. Under the merger agreement, Channel will acquire 100% of Pe

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

**media[555300]**

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2024 Earnings Call Transcript February 27, 2025Ligand Pharmaceuticals Incorporated misses on earnings expectations.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ETCompany ParticipantsMelanie Herman - Senior...

**media[552077]**

Robust financial performance driven by full year 2024 royalty revenue growth of 28% Reiterating 2025 financial guidance of $180-$200 million in revenues and ad

Capital will fund Castle Creek's D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa through topline data results Ligand invested $

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2024 financial results before the opening o

Ligand Pharmaceuticals stock is on the rise with optimistic analyst ratings and a plan for 20% annual revenue growth. Learn more about LGND stock here.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ETCompany ParticipantsMelanie Herman - Senior...

Roth analysis: Has volatility created a trigger warning for stocks?

Earnings call: Ligand Pharmaceuticals reports strong Q2 growth

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q2 2024 Earnings Call Transcript August 6, 2024Ligand Pharmaceuticals Incorporated misses on earnings expectations.

Ligand Pharmaceuticals Incorporated (NASDAQ:NASDAQ:LGND) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ETCompany ParticipantsTodd Davis - CEOTavo...

The following slide deck was published by Ligand Pharmaceuticals Incorporated in conjunction with their 2024 Q2 earnings call.